. Author manuscript; available in PMC: 2021 May 1.

Published in final edited form as: Am J Surg Pathol. 2020 May;44(5):665–672. doi: 10.1097/PAS.0000000000001421

Table 2:

FOXP1/SOX10 immunophenotypes in 173 salivary gland tumors. *This case was subsequently re-classified as ameloblastoma after consensus review.

	FOXP1+/SOX10−	FOXP1+/SOX10+	FOXP1−/SOX10−	FOXP1−/SOX10+
Basal cell adenoma (9 cases)	0/9 (0%)	8/9 (89%)	1/9 (11%)	0 (0%)
Adenoid cystic carcinoma (63)	0/63 (0%)	47/63 (75%)	2/63 (3%)	14/63 (22%)
Polymorphus adenocarcinoma (7)	0/7 (0%)	3/7 (43%)	1/7 (14%)	3/7 (43%)
Myoepithelioma (9 cases)	0/9 (0%)	3/9 (33%)	4/9 (44%)	2/9 (22%)
Pleomorphic adenoma (43)	2/43 (4%)	14/43 (33%)	8/43 (19%)	19/43 (44%)
Acinic cell carcinoma (7)	0/7 (0%)	6/7 (86%)	0/7 (0%)	1/7 (14%)
Salivary duct carcinoma (3)	0/3 (0%)	0/3 (0%)	3/3 (100%)	0/3 (0%)
Oncocytoma (9 cases)	0/9 (0%)	0/9 (0%)	9/9 (100%)	0/9 (0%)
Mucoepidermoid carcinoma (22 cases)	0/22 (0%)	0/22 (0%)	19/22 (86%)	3/22 (14%)
Low grade adenocarcinoma, NOS* (1 case)	1/1 (100%)	0/1 (0%)	0/1 (0%)	0/1 (0%)